Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report.

Cherrez-Ojeda I, Vanegas E, Felix M, Mata VL, Cherrez A.

BMC Dermatol. 2018 Oct 25;18(1):8. doi: 10.1186/s12895-018-0077-x.

2.

Improvement in the quality of life of patients with chronic spontaneous urticaria treated with omalizumab in real life.

Larrea-Baca I, Gurpegui-Resano M.

Enferm Clin. 2017 Nov - Dec;27(6):361-368. doi: 10.1016/j.enfcli.2017.03.010. English, Spanish.

PMID:
28457893
3.

Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.

Ghazanfar MN, Holm JG, Thomsen SF.

J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1761-1767. doi: 10.1111/jdv.15045. Epub 2018 May 29.

PMID:
29729103
4.

Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria.

Kitsioulis NA, Xepapadaki P, Roussaki-Schulze AV, Papadopoulos N, Zafiriou E.

Int Arch Allergy Immunol. 2017;172(3):161-166. doi: 10.1159/000458152. Epub 2017 Apr 6.

PMID:
28380487
5.

Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.

Nettis E, Cegolon L, Di Leo E, Canonica WG, Detoraki A; Italian OCUReL Study Group.

Ann Allergy Asthma Immunol. 2018 Mar;120(3):318-323. doi: 10.1016/j.anai.2017.12.007.

PMID:
29508719
6.

Successful Omalizumab treatment in HIV positive patient with chronic spontaneous urticaria: a case report.

Iemoli E, Niero F, Borgonovo L, Cossu MV, Piconi S.

Eur Ann Allergy Clin Immunol. 2017 Mar;49(2):88-91.

7.

Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.

Staubach P, Metz M, Chapman-Rothe N, Sieder C, Bräutigam M, Canvin J, Maurer M.

Allergy. 2016 Aug;71(8):1135-44. doi: 10.1111/all.12870. Epub 2016 Mar 31. Erratum in: Allergy. 2017 Sep;72 (9):1430.

PMID:
27010957
8.

Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.

Vestergaard C, Toubi E, Maurer M, Triggiani M, Ballmer-Weber B, Marsland A, Ferrer M, Knulst A, Giménez-Arnau A.

Eur J Dermatol. 2017 Feb 1;27(1):10-19. doi: 10.1684/ejd.2016.2905. Review.

PMID:
27882879
9.

Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population.

Kulthanan K, Tuchinda P, Chularojanamontri L, Likitwattananurak C, Ungaksornpairote C.

J Dermatolog Treat. 2017 Mar;28(2):160-165. doi: 10.1080/09546634.2016.1200710. Epub 2016 Jul 7.

PMID:
27388043
10.

Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.

Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E, Bradley MS, Canvin J, Rahmaoui A, Georgiou P, Alpan O, Spector S, Rosén K.

J Invest Dermatol. 2015 Jan;135(1):67-75. doi: 10.1038/jid.2014.306. Epub 2014 Jul 21. Erratum in: J Invest Dermatol. 2015 Mar;135(3):925.

11.

Efficacy of Omalizumab Treatment with Concomitant Antihistamines as Needed for Moderate, Refractory Chronic Spontaneous Urticaria.

Nettis E, Cegolon L, Macchia L, Zaza I, Calogiuri G, Di Leo E.

Acta Derm Venereol. 2018 Apr 16;98(4):446-448. doi: 10.2340/00015555-2886. No abstract available.

12.

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.

Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, Spector S, Maurer M.

J Allergy Clin Immunol. 2011 Sep;128(3):567-73.e1. doi: 10.1016/j.jaci.2011.06.010. Epub 2011 Jul 18.

PMID:
21762974
13.

Omalizumab chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.

Nettis E, Cegolon L, Di Leo E, Lodi Rizzini F, Detoraki A, Canonica GW; Italian OCUReL study group.

Ann Allergy Asthma Immunol. 2018 Oct;121(4):474-478. doi: 10.1016/j.anai.2018.06.014. Epub 2018 Jun 24. Erratum in: Ann Allergy Asthma Immunol. 2018 Dec;121(6):749.

PMID:
29949781
14.

Urticarial vasculitis: a unique presentation.

Stigall LE, Sigmon JR, Leicht SS.

South Med J. 2009 May;102(5):531-3. doi: 10.1097/SMJ.0b013e3181a0ae4c.

PMID:
19373142
15.

Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.

Kaplan A, Ferrer M, Bernstein JA, Antonova E, Trzaskoma B, Raimundo K, Rosén K, Omachi TA, Khalil S, Zazzali JL.

J Allergy Clin Immunol. 2016 Feb;137(2):474-81. doi: 10.1016/j.jaci.2015.08.023. Epub 2015 Oct 21.

16.

The efficacy and safety of omalizumab in refractory chronic spontaneous urticaria: real-life experience in Turkey.

Bulur I, Bulbul Baskan E, Ozdemir M, Balevi A, Kocatürk Göncü E, Altunay I, Gönül M, Ergin C, Ertam İ, Erdoğan HK, Bilgin M, Mustafa Teoman E.

Acta Dermatovenerol Alp Pannonica Adriat. 2018 Sep;27(3):121-126.

17.

Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study.

Hide M, Igarashi A, Yagami A, Chinuki Y, Inomata N, Fukunaga A, Kaiser G, Wang J, Matsushima S, Greenberg S, Khalil S.

Allergol Int. 2018 Apr;67(2):243-252. doi: 10.1016/j.alit.2017.10.001. Epub 2017 Nov 1.

18.

Validity and responsiveness of the Urticaria Activity and Impact Measure: A new patient-reported tool.

Maurer M, Mathias SD, Crosby RD, Rajput Y, Zazzali JL.

Ann Allergy Asthma Immunol. 2018 Jun;120(6):641-647. doi: 10.1016/j.anai.2018.03.012. Epub 2018 Mar 19.

19.

Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria.

Ferrer M, Boccon-Gibod I, Gonçalo M, İnalöz HS, Knulst A, Lapeere H, Parthasaradhi A, Stingl G, Tagka A, Valenzuela F, Yeung J, Thomsen SF.

Eur J Dermatol. 2017 Oct 1;27(5):455-463. doi: 10.1684/ejd.2017.3085.

PMID:
29084635
20.

Treatment of chronic autoimmune urticaria with omalizumab.

Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK.

J Allergy Clin Immunol. 2008 Sep;122(3):569-73. doi: 10.1016/j.jaci.2008.07.006.

PMID:
18774392

Supplemental Content

Support Center